The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…
Event to be held October 14th at 4 p.m. EST October 09, 2025 07:00 ET | Source: Gain Therapeutics, Inc.…
NEW DELHI, Oct. 6, 2025 /PRNewswire/ -- ACKO's Grand Traffic Challan Report gives a clear picture of how Indian motorists…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…
HelloFresh and its partners celebrate 10 million meals donated through Meals with Meaning, a program launched in 2020.NEW YORK--(BUSINESS WIRE)--This…
June 21, 2025 18:00 ET | Source: BioAge Labs, Inc. Treatment with apelin receptor agonist enhanced glycemic control and demonstrated…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…